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The endothelial lining of the vasculature is exposed to a large variety of biochemical and hemodynamic stimuli with different
gradients throughout the vascular network. Adequate adaptation requires endothelial cells to be highly plastic, which is reflected
by the remarkable heterogeneity of endothelial cells in tissues and organs. Hemodynamic forces such as fluid shear stress and
cyclic strain are strong modulators of the endothelial phenotype and function. Although endothelial plasticity is essential during
development and adult physiology, proatherogenic stimuli can induce adverse plasticity which contributes to disease. Endothelial-
to-mesenchymal transition (EndMT), the hallmark of endothelial plasticity, was long thought to be restricted to embryonic
development but has emerged as a pathologic process in a plethora of diseases. In this perspective we argue how shear stress and
cyclic strain can modulate EndMT and discuss how this is reflected in atherosclerosis and pulmonary arterial hypertension.
1. Introduction
Mechanical forces, laminar shear stress (LSS), and cyclic
strain (CS) are two major and well-established regulators
of vascular development and adaptation (reviewed in [1–
3]). Vasculogenesis, which marks the onset of embryonic
vascularization, is driven by hypoxia and initiated by the dif-
ferentiation of endothelial cells frommesodermal angioblasts
[4]. Herein, hypoxia inducible factor 1 alpha (HIF1𝛼) induces
the expression of vascular endothelial growth factor (VEGFa)
which results in endothelial differentiation and proliferation.
The endothelial cells derived from the blood islands form
a vascular network known as the primitive capillary plexus
[5]. This plexus is highly uniform without a clear vascular
hierarchy.
With the interconnection of the vascular plexus and
major vessels a functional loop is formed and, as the heart
begins to beat, the physical flow of fluid is introduced
[6]. Arteriogenesis ensues the remodeling of the vessels
to accommodate the physical forces associated with the
increased pressures and flow. The pulsatile nature of the
blood flowgenerated by the beating heart produces a complex
interplay between two distinct mechanical forces, namely,
fluid shear stress (FSS), the frictional force exerted by the
flow of blood, and cyclic strain (CS), which results from
the distensibility of the vessel wall caused by pulsations and
increased hydrostatic pressures. Adaptation to these forces,
known as angioadaptation, results in a hierarchical vascular
tree composed of arteries, arterioles, capillaries, venules, and
veins [7].
In the adult vasculature, hemodynamic forces play a
major role in the maintenance of vessel homeostasis [8]. The
most important intimation for a role of hemodynamic forces
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Figure 1:Mechanisms of endothelial-mesenchymal transition. EndMT is induced by TGF𝛽-dependent and TGF𝛽-independentmechanisms.
Canonically, TGF𝛽-induced activation of SMAD2/3 induces the expression of mesenchymal genes and repression of endothelial genes.
Noncanonically, TGF𝛽-induced activation of Erk1/2 and p38 MAPK activate the transcription factor Snail which induces mesenchymal
differentiation and inhibits VE-Cadherin expression. Inflammatory signals and increased ROS production facilitate EndMT by increasing
endogenousTGF𝛽 expression, in anNF𝜅B-dependentmanner, creating a feed forward signalingmechanism.AT1 receptor can induce EndMT
through activation of NADPH oxidase, resulting in increased ROS production and reduction of eNOS expression and activity.
in vascular homeostasis is found in the focal nature of most
vascular diseases. For example, despite the fact that most risk
factors for atherosclerosis development and progression are
present at the systemic level, this inflammatory arterial dis-
ease preferentially develops in regions which are character-
ized by disturbed hemodynamic flow, typically encountered
at the outer walls of vascular bifurcations and at the inner
wall of vascular curvatures [9, 10]. Indeed, disturbances of
fluid shear stress levels encountered at these locations are
predictors of plaque location [11], associate with the increased
mass transport of low-density lipoproteins (LDL)which build
up the plaques [12], and are major determinants of plaque
transition from stable plaques to high-risk unstable plaques
and plaque rupture [13].
In recent years, it has become apparent that the endothe-
lium plays a pivotal role in the development and progression
of cardiovascular diseases [14–16]. The endothelial lining
of the vasculature is exposed to a large variety of stimuli
which require the endothelium to be highly plastic [17],
as is reflected by the remarkable heterogeneity of endothe-
lial cells in tissues and organs. Although this endothelial
plasticity is essential during homeostasis, during disease,
pathological stimuli might induce adverse plasticity which
can contribute to disease. Herein, endothelial-mesenchymal
transition (EndMT) and its contribution to neointima forma-
tion [18–21] is a perfect example.
In this perspective, we focus on how hemodynamic
forces, that is, shear stress and cyclic strain, are sensed by the
endothelium, how these forces modulate EndMT, and how
this is reflected in vascular disease.
2. Endothelial-to-Mesenchymal Transition:
The Hallmark of Endothelial Plasticity
Endothelial-to-mesenchymal transition (EndMT) was orig-
inally described as an embryonic phenomenon involved
in cardiac valve formation [22]. EndMT has mainly been
studied in vitro, where it is characterized by the loss of
cell-cell adhesions and changes in cell polarity, resulting
in a spindle-shaped morphology. Endothelial cell markers
such as VE-Cadherin and PECAM-1 are repressed, whilst
the expression of mesenchymal cell markers such as 𝛼-
smoothmuscle actin (𝛼-SMA) and calponin is enhanced [23–
26]. Functionally, endothelial cells acquire myofibroblast-like
characteristics with contractile function, enhancedmigratory
phenotype, and increased extracellular matrix production
[24]. In EndMT, endothelial functions, such as antithrombo-
genicity and angiogenic sprouting capacity, are lost [23, 24].
Through extensive studies on EndMT in vitro, we have
gained in-depth knowledge of the signaling cascades that
regulate EndMT (Figure 1). Many signaling pathways are
involved in the induction and progression of EndMT,
wherein the transforming growth factor 𝛽 (TGF𝛽)/bone
morphogenetic protein (BMP) superfamily plays a pivotal
role.
In endothelial cells, canonical TGF𝛽 signaling occurs
through the type II TGF𝛽 receptor (TGF𝛽R2) which activates
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the type I TGF𝛽 receptorActivin-like kinase (ALK) 5, activat-
ing receptor-regulated Smad2/3, and leads to inhibition of cell
proliferation and induction of EndMT [27–30]. In contrast,
TGF𝛽 and bonemorphogenetic proteins (BMP) can also bind
the BMP type I receptor, ALK1, which activates receptor-
regulated Smad1/5/8 and induces proliferation and inhibits
EndMT [27–29]. The common-mediator Smad4 interacts
with the receptor-regulated Smads and is required for sig-
naling. The inhibitory Smads 6 and 7 block activation of the
receptor-regulated Smads and thus inhibit TGF𝛽 signaling.
The balance between ALK1 and ALK5 signaling pathways is
partially regulated by an accessory type III TGF𝛽 receptor
called endoglin, which stimulates ALK1-induced Smad1/5/8
responses and thus indirectly inhibits ALK5 signaling [29].
Besides canonical TGF𝛽 signaling, TGF𝛽 can induce
EndMT noncanonically through the activation of the ERK1/2
and p38 MAPK signaling pathways and the downstream
induction of the mesenchymal transcription factor Snail [31,
32] (Figure 1). Furthermore, Notch is known to promote
TGF𝛽-induced EndMT shifting the balance between differ-
ent ALK1 and ALK5 signaling pathways in favor of ALK5
[33, 34].
Other signaling mechanisms can also induce EndMT,
albeit often indirectly involving TGF𝛽 signaling. Proinflam-
matory molecules, such as IL1𝛽 and TNF𝛼, synergize with
TGF𝛽 in the induction of EndMT [35–37]. Besides, IL1𝛽 and
TNF𝛼 induce the expression of Snail and Slug, two pivotal
transcription factors in EndMT [38–40]. Reactive oxygen
species (ROS) are potential stimulators of EndMT (Figure 1)
by inducing endogenous TGF𝛽 expression and activating
latent TGF𝛽 [41]. TGF𝛽 also stimulates ROS production,
resulting in a positive feedback loop [41]. Besides, ROS
activates NF𝜅B signaling which acts in synergy with TGF𝛽
in induction of EndMT [36, 42].
The AT1 receptor (angiotensin II receptor type I), a
member of the G-protein coupled receptor family, mediates
EndMT of human aortic endothelial cells in vitro [43] as well
as in cardiac endothelial cells in vivo [44, 45].Angiotensin II-
induced EndMT can bemediated both by release of cytokines
such as TGF𝛽 or through changes in the redox status of EC
by the activation of NADPH oxidase system [45] which leads
to higher superoxide production, NF𝜅B activation [42], and
lower NO bioavailability through uncoupling eNOS [46, 47]
(Figure 1).
In summary, TGF𝛽 signaling plays a dominant role as
inducer of EndMTdirectly via both canonical and noncanon-
ical signaling pathways. In recent years, it has become evident
that EndMT is not restricted to embryogenesis but can also
occur in adult life, where it contributes to organ and muscle
fibrogenesis [48–52], cancer [53], and atherosclerosis [18–
20]. In the following section, we argue how hemodynamic
forces can modulate EndMT and how these mechanisms are
reflected by vascular disease.
3. Hemodynamic Forces as
Modulators of EndMT
3.1. Go with the Flow: Laminar Shear Stress Is a Hemodynamic
Force Transduced by the Endothelium. Hemodynamic forces
play a pivotal function in the maintenance of the vascular
integrity. It is well established that high uniform laminar
shear stress (LSS) has atheroprotective effects [54], which is
evidenced by the occurrence of endothelial dysfunction [55],
aneurysms [56], and atherosclerosis [57–59] at sites where
LSS is reduced or worse, absent or disturbed.
A variety of signaling cascades are involved in endothelial
mechanotransduction of LSS; however, identifying which
pathways are primary or secondary to LSS sensing remains
elusive as the initial mechanosensory complexes are not
completely identified.
Endothelial cells sense LSS through a number of mecha-
nisms including the endothelial glycocalyx [60–62], growth
factor receptors [63, 64], cell-cell adhesion molecules [65,
66], integrins [67], and G-protein-coupled receptors [68–
70] (Figure 2). The endothelium is covered by a slimy layer
of plasma proteins and glycoproteins, known as the glyco-
calyx, which is an organized hydrated mesh of negatively
charged membranous macromolecules, proteoglycans, and
glycosaminoglycans [71]. The proteoglycan core proteins
are the membrane-bound glypican and the transmembrane
syndecans. Syndecans directly associate with the cytoskeleton
[72] andmay thus directly transmitmechanical stresses to the
nucleus or remote mechanotransducers [73, 74] (Figure 2).
Indeed, disruption of the endothelial glycocalyx either genet-
ically or by pharmacological inhibitors of glycocalyx pro-
ducing enzymes renders the endothelium shear insensitive
[60–62]. Although insights into glycocalyx signaling remain
elusive, syndecans and glypicans are known to associate with
the 𝛽1 integrins and mediate the activity of focal adhesion
kinase (FAK) through protein kinase C-alpha (PKC𝛼) [61,
62, 67, 73], resulting in the activation of Akt, Rho, and
the endothelial nitric oxide synthase (eNOS). Combined,
glycocalyx signaling enhances endothelial survival andmain-
tenance of the endothelial barrier (Figure 2).
The protein complex consisting of PECAM-1, VEGFR2,
and VE-Cadherin is a junctional mechanosensory com-
plex that transduces hemodynamic forces into biochemi-
cal responses [75]. In this mechanosensory complex, VE-
Cadherin functions as an initial adaptor which initiates the
formation of the signaling complex, whereas PECAM-1 can
directly transducemechanical forces to the cytoskeleton [65].
VEGFR2, in association with VEGFa, initiates bidirectional
activation of PI3K and MEKK3 which cause the downstream
activation of Akt and MEK5/Erk5 signaling (Figure 2). Col-
lectively, signaling through this junctional complex results
in the activation of a number of transcription factors [63,
64] described below and loss of any one of its components
ameliorates the endothelial response to LSS [2].
Additionally, the membrane bound G-protein-coupled
receptors of type G𝛼q/G𝛼11 transmit mechanical forces in
part through the activation of PI3K and intracellular calcium
signaling [76–78]. Activation of G𝛼q/G𝛼11 proteins results
in the activation of Akt and increased activation of eNOS
(Figure 2).
Thus, the endothelium is highly sensitive to laminar shear
stress and endothelial mechanosensing and transduction
is achieved through a variety of cell-matrix and cell-cell
receptor complexes. Endothelial mechanotransduction by







































Figure 2: Endothelial shear stress sensing. Endothelial cells sense LSS through a number of mechanisms. Shear stress sensing through
the endothelial glycocalyx is mediated by the syndecans and glypicans, which activate PKC signaling. Luminal 𝛽1-integrins also anchor
to the endothelial glycocalyx and activate focal adhesion kinase (FAK). The G-protein-coupled receptors of G𝛼q/G𝛼11 sense shear stress and
activate downstream PI3K and Ca2+ signaling.The junctional mechanosensory complex consisting of PECAM-1, VEGFR2, andVE-Cadherin
mediates PI3K and MAPK (MEKK3) signaling. Signaling through these mechanosensors culminates in activation of Akt, PKA, AMPK, and
MEK5/Erk5 which collectively maintain the endothelial phenotype.
these protein complexes culminates in the activation of
the Akt, PKA, AMPK, and MEK5/Erk5 signaling cascades
that ensure the maintenance of endothelial homeostasis and
inhibit EndMT (Figure 2).
3.2. The Atheroprotective Effects of Laminar Shear Stress and
the Inhibition of EndMT. It is well established that the extra-
cellular signal-related kinase (Erk) 5, also known as MAPK7
and big-mitogen kinase-1 (BMK-1), has atheroprotective
effects [54, 79, 80]. Erk5 is the onlymitogen-activated protein
kinase (MAPK) which is continuously activated by uniform
LSS in vitro [18, 81] and several lines of evidence suggest
that Erk5 transmits its atheroprotective effects through the
activation of the transcription factors of the Kru¨ppel-like
factor (KLF) family [18, 82–84].
First, Kru¨ppel-like factor 2 (KLF2) is an important
shear stress-activated transcription factor, which exerts anti-
inflammatory effects through inhibition of nuclear factor
kappa B (NF𝜅B) activation [85] and anticoagulant effects
by induction of thrombomodulin and repression of tissue
factor and plasminogen activator inhibitor (PAI-1) [86].
Besides, KLF2 regulates antioxidative signaling [87], induces
quiescence [88], and inhibits VEGFa-induced angiogenesis,
barrier disruption, and cell proliferation [89].
Second, KLF2 inhibits the phosphorylation and nuclear
translocation of Smad2 through induction of inhibitory
Smad7 [90]. Moreover, KLF2 also suppresses the activator
protein 1 (AP-1), an important cofactor for TGF𝛽-dependent
transcription [90].Thus, KLF2might directly inhibit EndMT
by suppressing TGF𝛽 signaling.
The expression of KLF4, a close family member of KLF2,
is similarly induced upon exposure to LSS [91, 92]. Significant
conservation exists between KLF2 and KLF4 [82, 93]. In
fact, almost 60% of MEK5 regulated genes are coregulated
by KLF2 and KLF4 [93]. Similar to KLF2, KLF4 exerts anti-
inflammatory effects through suppression of NF𝜅B activity
[94]. KLF4-specific targets include forkhead boxO1 (FOXO1)
and vascular endothelial growth factor (VEGF) [93], both of
which are known to inhibit TGF𝛽 signaling [48, 95].
Third, KLF4 plays an important role in cell-cycle regu-
lation and differentiation. KLF4 increases the expression of
several inhibitors of proliferation, while genes that promote
proliferation are repressed [88, 96, 97]. As such, KLF4
might partially be responsible for the quiescence observed in
endothelial cells exposed to high levels of uniform LSS.
Fourth, KLF4 is known to suppress mesenchymal
differentiation through several mechanisms. KLF4 inhibits
myocardin expression, a potent coactivator of serum
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response factor (SRF) [98, 99], and prevents SRF/myocardin
from associating with mesenchymal gene promoters [100].
KLF4 can also directly bind the TGF𝛽 control element
(TCE) in the promoter of mesenchymal genes, preventing
transcription [101]. Furthermore, KLF4 interacts with
Smad3, inhibiting its binding to Smad binding elements
(SBE) and preventing transcription of mesenchymal genes
[102]. Interestingly, KLF4 is also known to transcriptionally
regulate VE-Cadherin [103]. Thus KLF4 might inhibit
EndMT via multiple mechanisms.
Last, KLF2 and KLF4 can inhibit EndMT through the
inhibition of ROS formation by eNOS-induced stimulation
of superoxide dismutase (SOD), scavenging of ROS through
NO production [104, 105], and facilitation of mitochondrial
biogenesis [106].
In addition to the atheroprotective effects mediated by
the KLFs, LSS induces the expression of inhibitor of DNA
binding/inhibitor of differentiation proteins 1–3 (Id1–3) [107].
These dominant-negative regulators of basic helix-loop-helix
DNA-binding transcriptional regulators play a role in lineage
commitment, cell cycle control, and cell differentiation [108].
Id2 and Id3 repress Smad2-mediated gene transcription [109]
and ectopic expression of Id2 and Id3 inhibits EMT [110].
Besides, Id3 is downregulated during EndMT [24] and Id1
has been shown to promote survival of endothelial cells and
preserve the integrity of lung microvascular endothelial cells
[111].
In summary, LSS plays a major role in endothelial
homeostasis, wherein mechanical stimuli are transduced
into biochemical signals which culminate in the expression
of the KLF transcription factors. KLF2 and KLF4 govern
endothelial thrombogenicity, inflammatory phenotype, per-
meability, proliferation, and redox state through a variety
of mechanisms. In addition, the KLF transcription fac-
tors inhibit mesenchymal gene expression. Hence, the LSS-
induced expression of the KLF transcription factors is pivotal
in the inhibition of EndMT.
3.3. Disturbed Shear Stress: Inducer or Permitter of EndMT?
In contrast to the beneficial effects of LSS, oscillatory or
nonuniform shear stress, further referred to as disturbed
shear stress (DSS), has opposing effects on endothelial home-
ostasis; that is, DSS causes EC dysfunction. DSS is known
to induce endothelial inflammatory activation [112–114]. DSS
reduces the endothelial antithrombogenicity and increases
the formation of reactive oxygen species (ROS), which
further adds to the inflammatory activation and profibrotic
signaling. During arteriogenesis, the screw-like curvatures
of the collaterals convert LSS to DSS, which stimulates
endothelial proliferation and MCP-1 activation, resulting in
the recruitment of monocytes that are essential for remod-
eling of the vascular structure [115]. These mechanisms are
reiterated during vascular pathology. Areas exposed to DSS
are characterized by a high influx of leukocytes, which gen-
erates a microenvironment with excessive ROS production,
high levels of TGF𝛽, and inflammatory mediators such as
IL1𝛽, which all favor EndMT [36].
DSS induces ROS formation through several mech-
anisms. DSS leads to increased nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase (NOX) activity
(Figure 4) which results in ROS production [116]. NADPH
oxidase activity can induce xanthine oxidoreductase (XO), an
important source of ROS [117]. Next, expression of NOX4, a
subunit of vascular NADPH oxidase, is increased in response
to DSS resulting in increased LDL oxidation [118]. Adding
to this, intracellular glutathione, a powerful antioxidant, is
greatly decreased by DSS [119].
DSS can also induce EndMT through direct activation
of TGF𝛽 signaling (Figure 4). BMP4 is a potent inducer of
EndMT [48], expression of which is inhibited by LSS [120].
In contrast, exposure to DSS induces BMP4 [121] expression
in endothelial cells and contributes to ROS production and
NF𝜅B activation [122]. Additionally, DSS induces TGF𝛽
expression and activation in an NF𝜅B-dependent manner
[123].
Taken together, high LSS can inhibit EndMT via multiple
mechanisms, either directly or indirectly interfering with
TGF𝛽 signaling. DSS suppresses these protective mecha-
nisms making endothelial cells more prone to microenviron-
mental cues which favor EndMT. Besides, DSS can induce
EndMT directly through induction of BMP4 or via increased
ROS production. Indeed, exposing aortic endothelial cells
(which normally are exposed to LSS) to DSS by aortic
banding efficiently induces EndMT in vivo in the absence of
other stimuli [18].Therefore, DSS acts both as a permitter and
inducer of EndMT by either suppressing protective signaling
or by directly inducing the transition process.
3.4. Cyclic Strain. Cyclic strain (CS) is defined as the repeti-
tive mechanical deformation of the vessel during the cardiac
cycle. Vascular CS can vary from 2 to 20% in vivo as a
result of arterial wall expansion and contraction in response
to pulsatile pressure changes [124]. CS plays an important
role in the modulation of cell proliferation, migration,
apoptosis, morphological changes, and alignment through
the production of vasoactive substances such as nitric
oxide (NO) [125], endothelin (ET-1), [126] and antioxidants
[127, 128].
Physiologically, the level of CS is around 6–10% but this
strongly varies throughout the vasculature. CS can increase
with hypertension and artificial pulmonary ventilation (10%
to 20%) and decrease with ageing due to vascular stiffening
or acutely due to sepsis (2%–6%) [129]. CS levels up to
10% do not induce endothelial injury [130] but inhibit
endothelial apoptosis through activation of PI3-kinase and
Akt. In contrast, CS levels of over 15% induce apoptosis
[131].
Endothelial cells sense CS through a number of mecha-
nisms involving stretch-activated ion channels, integrins, and
G-protein-coupled receptors. Stretch-activated ion channels
play a pivotal role in CS sensing. Stretching of endothelial
cells opens the ion channels allowing extracellular Ca2+ to
enter the cell, thereby activating downstream phospholipase
C (PLC) signaling [132] (Figure 3). Additionally, the cell-
matrix adhesion families of integrins mediate CS signaling
in endothelial cells by the activation of focal adhesion kinase
(FAK) and integrin-linked kinase (ILK) complexes that result

























Figure 3: Endothelial cyclic strain sensing. Endothelial cells sense CS through a number of mechanisms. Stretch-sensitive ion channels
undergo a conformational change during stretch which opens up the channel and induces Ca2+ flux from the extracellular space into the
endothelial cell. Basal 𝛽1-integrins anchor to the endothelial basement membrane and activate focal adhesion kinase (FAK) and the integrin-
linked kinases (ILK). The G-protein-coupled receptors of G𝛼q/G𝛼11 sense CS and activate downstream PI3K and Ca
2+ signaling. Signaling
through these stretch sensors culminates in activation of Akt, PKC, PLC, and Erk1/2 which collectively maintain the endothelial phenotype.
in the downstreamactivation of the small GTPase family Rho,
PI3K, and Akt (Figure 3). Combined, these signals result in
changes in endothelial morphology and the regulation of cell
survival and cytokine production. However, to what extent
CS induces these effects and the relation between the mag-
nitude of CS and the endothelial integrin-mediated response
remain elusive [133, 134].The heterotrimeric G𝛼q/𝛼11 subunit
of the G protein family is rapidly activated by CS and the
intensity is related to the magnitude of the strain applied
[135]. AT1 receptors bind and signal through all members of
the G-protein family and are activated by mechanical forces
in vitro and in vivo, independently of angiotensin II [136, 137].
Stimulation of the CS sensors causes downstream activa-
tion of small GTPases that are essential for the biochemical
transduction of the mechanical stimulus. The most exten-
sively characterizedmembers areRho, Rac, andCdc42,which
have distinct effects on actin cytoskeleton, cell adhesion, and
cell motility [138]. Rho kinase induces assembly of stress
fibers and focal adhesions and Rac plays an important role
in junction formation and integrity of the endothelial barrier
[139]. The activity of the Rho pathway determines the direc-
tion and extent of stretch-induced stress fiber orientation
in endothelial cells. This demonstrates on one hand that
physically stressing a cell determines Rho activity (in a linear
fashion) and that Rho activation directly correlates with
physical shape shifting of cells through cytoskeletal reorga-
nization [140, 141]. Also, preconditioning of endothelial cells
at 18% CS enhanced the effects of prothrombotic stimuli
to induce permeability of the endothelial monolayer, while
5% CS prevents thrombin-induced disruptive response and
accelerates barrier recovery [142]. Corroboratively, CS in the
10–20% range causes activation of Rho and a reduction of
basal Rac activity (Figure 4). In contrast, 5% stretchmaintains
the balance between Rho and Rac activity [143, 144]. These
studies suggest a major role for amplitude-dependent CS in
regulation of the endothelial barrier.
3.5. Cyclic Strain Sets the Stage for EndMT. Enhanced CS
(>10%) potentiates EndMT of valvular endothelial cells in a
manner dependent on both strain magnitude and direction
[145]. Modest CS (10%) induces EndMT via amplified TGF𝛽1
signaling, while high CS (20%) activates wnt/𝛽-catenin sig-
naling [145], a known inducer of EndMT in aortic endothelial
cells [146, 147]. Both intensities decreased VEGFa signaling,
a known inhibitor of EndMT [48]. Notably, mechanical
stretch induces epithelial-to-mesenchymal transition (EMT)








































Figure 4: Disturbed shear stress and high cyclic strain signaling in endothelial-mesenchymal transition. Disturbed shear stress induces
EndMT through several mechanisms. Disturbed shear stress activates latent TGF𝛽 by liberating it from LAP, after which TGF𝛽 can induce
Smad2/3 signaling. Disturbed shear stress induces the expression of BMP4 which causes ROS formation and the activity of NF𝜅B. Lastly,
disturbed shear stress inducesNOX andXOactivity resulting in the generation of ROS. All these signaling intermediates culminate in EndMT.
Increased cyclic strain (>10%) induces the FAK-dependent activation of Rho-kinases. Rho activity causes the translocation of VE-Cadherin
from the cell membrane into cytoplasmic vesicles and causes a reduction in endothelial cell-cell contacts. Cyclic strain-dependent Wnt-𝛽-
catenin activity induces EndMT in part by the induction of Snail and Slug and the further activation of Rho activity.
of renal tubular epithelial cells by induction of TGF𝛽1 mRNA
expression and activation of latent TGF𝛽 [146].
VE-Cadherin is a central component of endothelial
adherens junctions. VE-Cadherin is a transmembrane glyco-
protein that complexes via its cytoplasmic tail to 𝛽-catenin,
which links VE-Cadherin to the cortical actin cytoskeleton
[148]. The cellular localization of VE-Cadherin is dependent
on the small GTPases Rho and Rac that when appropri-
ately balanced stabilize VE-Cadherin at the cell membrane
[149].
EndMT results in a loss of barrier function, that is,
increased permeability, which correlates with loss of VE-
Cadherin at the cell surface (Figure 4). In response to
the increase of Rho activity by high levels of CS [141],
VE-Cadherin is translocated from the membrane into the
cytoplasm. The concomitant loss of complexed 𝛽-catenin
and its nuclear translocation might therefore be a sec-
ondary mediator of EndMT. Indeed, Rho activity plays a
pivotal role in TGF𝛽1-induced EMT through induction of
cytoskeleton remodeling and activation of the smoothmuscle
actin (SMA) promoter [150] and 𝛽-catenin/Rho signaling
efficiently induces EndMT [32, 147, 151, 152]. This implies
that supraphysiological CS is a direct inducer of EndMT
(Figure 4).
Vascular remodeling is accompanied by changes in extra-
cellularmatrix (ECM) turnover, which result from alterations
in the balance of matrix deposition and its proteolytic
degradation. Matrix metalloproteinases (MMPs) represent
the main group of proteases involved in remodeling of ECM
[153]. An imbalance between the activity of MMPs and their
tissue inhibitors (TIMPs) contributes to adverse remodeling.
MMP2 induces matrix degradation during vascular remod-
eling [154] and TGF𝛽2-induced EndMT is characterized
by a marked increase in MMP2 [151]. Interestingly, biaxial
CS induces endothelial MMP2 expression and regulates its
secretion and activity [130, 155]. Additionally, in a model
for intimal hyperplasia, stretched human saphenous vein
grafts increased expression and activity ofMMP2 throughout
the vascular wall [156]. Taken together, cyclic strain induces
MMP2 expression in endothelial cells thereby facilitating
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the migratory and proliferative phenotype acquired through
EndMT.
Clearly, cyclic strain is not an ON/OFF switch of patho-
logical vascular remodeling and EndMT, illustrated by the
fact that endothelial cells react to CS in an amplitude-
dependent manner. Stretching of endothelial cells may exert
beneficial effects in physiological conditions (uniaxial, 5%–
10%) but might induce advert effect during pathologies
(strains <6% or >10%) such as hypertension. Reduced vas-
cular distensibility is a common feature of vascular aging and
is correlated with an increased risk of cardiovascular disease
[157]. Loss of vessel wall compliance with age or increased
CS during disease may blunt or aggravate the endothelial
response to mechanical strain and induce EndMT. Whether
and how this might contribute to pathophysiology remains to
be determined.
3.6. Hemodynamic Forces Act in Concert. It should be empha-
sized that, for clarity reasons, LSS and CS were discussed
as separate entities, yet they act in concert in vivo. For
technical reasons, few studies have integrated both forces.
However, fragmented evidence indicates that synchronicity
between LSS and CS is important for vascular homeostasis,
showing that asynchronicity between these hemodynamic
forces induces a proatherogenic response through reduced
expression of eNOS and cyclooxygenase-2 and increased
expression of endothelin-1 and NF𝜅B [158–160]. These find-
ings illustrate the importance of studying both entities in
combination.
4. Hemodynamic Forces, EndMT, and
Vascular Disease
EndMT contributes to vascular pathologies such as cardiac
fibrosis [44, 50, 161], atherosclerosis [18, 20, 79], vascular
restenosis [162], and the remodeling observed with pul-
monary arterial hypertension [26]. As stated previously, the
focal nature of these diseases, despite their systemic or genetic
risk factors, intimates a pivotal role for hemodynamic forces
in modulating these pathologies.
In atherosclerosis, levels of activated Smad2 are elevated
especially at areas exposed to DSS [163]. Also, endothelial
BMP4 expression is elevated at the site of atheroma formation
and in calcifed atherosclerotic plaques, characterized by
DSS [164], where also increased levels of ROS production
are found [165], which all favor EndMT induction and
progression. Indeed, at these sites, EndMT contributes to
intimal hyperplasia and atherosclerosis development [18, 20].
In patients with pulmonary arterial hypertension (PAH),
elevations in pulmonary venous pressure or long-term
increases in blood flow such as those produced by intrac-
ardiac shunts result in increased hemodynamic loads and
cause structural changes of the pulmonary vasculature.
The remodeling response is characterized by endothelial
dysfunction, intimal hyperplasia, muscularization of small
peripheral vessels, and wall thickening in proximal ves-
sels [166]. The increased hemodynamic load results in
increased CS and DSS originating from flow reversal in
the pulmonary trunk due to the curved path of the blood
flow and dilatation of the pulmonary artery [167]. Pul-
monary artery endothelial cells from patients with PAH
display a hyperproliferative, apoptosis-resistant phenotype
[168] concomitant with EndMT [24]. Interestingly, expres-
sion of the Early growth response protein 1 (Egr-1) is ele-
vated in experimental flow-associated PAH [169, 170] and
in the vessels of PAH patients with media hypertrophy and
neointimal lesions, including plexiform lesions [169]. Egr-
1 induces the expression of Snail and Slug, two important
mediators of EndMT [171–173], which argues for a definite
role of EndMT in the pathogenesis of PAH, as was recently
evidenced in human PAH and in experimental models for
PAH [19, 174, 175].
Besides, certain patients with familial PAH have muta-
tions of the bone morphogenetic protein (BMP) receptor
type II (BMPR2) gene or Activin-like kinase 1 (ALK1) gene
[176, 177]. Under normal conditions, these receptors can
stimulate Smad1/5/8 signaling in endothelial cells which
inhibits EndMT [27, 28, 178]. Hence, impaired BMPR2 or
ALK1 signaling renders the pulmonary endothelial cells from
these patients more prone to EndMT. BMPR2 deficient
rats show spontaneous pulmonary vascular remodeling with
enhanced expression of Twist-1, an inducer of EndMT [175].
Corroboratively, adenoviral BMPR2 gene delivery to the
pulmonary vascular endothelium in experimental models of
PAH reduces the vascular remodeling [179].
5. Conclusion
In conclusion, hemodynamic forces clearly modulate vas-
cular homeostasis and endothelial plasticity. Exposure of
endothelial cells to proper amplitudes of LSS and CS safe-
guard the endothelial integrity through a variety of signaling
cascades. Deviations in these hemodynamic forces, both by
ageing or pathology, results in adverse endothelial plasticity
and culminates in EndMT. Current advances on endothelial
mechanotransduction can provide us withmany new insights
into the regulation of endothelial plasticity.
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